AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32219675 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 264
Study 32220010 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement/repair (MVR)
Number of subjects: 42
Study 32220591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced magnetic resonance lymphangiography (DCMRL)
Number of subjects: 16
Study 32220591 — intervention group
Group type: EXPERIMENTAL
Intervention: DCMRL
Number of subjects: 16
Study 32220908 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle until disease progression, death, or unacceptable toxicity.
Number of subjects: 100
Study 32220908 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib-related TEAEs
Number of subjects: 100
Study 32220910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 24218
Study 32221013 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Number of subjects: 63
Study 32221013 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical NK cell infusion
Number of subjects: 63
Study 32221013 — intervention group
Group type: EXPERIMENTAL
Intervention: NK cells
Number of subjects: 63
Study 32221013 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenously reconstituted NK cells
Number of subjects: 63
Study 32221099 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoxygenation with 100% O2 for 3 minutes in adults
Number of subjects: 1921
Study 32221099 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of opioids during RSI in adults
Number of subjects: 1921
Study 32221099 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the Sellick manoeuvre in adults
Number of subjects: 1921
Study 32221099 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line medications for haemodynamically stable adults: propofol
Number of subjects: 1921
Study 32221099 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line medications for haemodynamically stable adults: suxamethonium
Number of subjects: 1921
Study 32221099 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual ventilation (inspiratory pressure <12 cmH2O) in adults
Number of subjects: 1921
Study 32221099 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoxygenation with 100% O2 for 3 minutes in paediatric patients
Number of subjects: 1921
Study 32221099 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of opioids during RSI in paediatric patients
Number of subjects: 1921
Study 32221099 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the Sellick manoeuvre in paediatric patients
Number of subjects: 1921
Study 32221099 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual ventilation (inspiratory pressure <12 cmH2O) in paediatric patients
Number of subjects: 1921
Study 32221099 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line medications for haemodynamically stable children: propofol
Number of subjects: 1921
Study 32221099 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line medications for haemodynamically stable children: rocuronium
Number of subjects: 1921
Study 32221675 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC-treated graft (NAC-enriched tumescent fluid)
Number of subjects: 15
Study 32221675 — intervention group
Group type: COMPARATOR
Intervention: Control graft (standard tumescent fluid)
Number of subjects: 15
Study 32221866 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 0.075% + Diclofenac 2%
Number of subjects: 746
Study 32221866 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 0.075%
Number of subjects: 746
Study 32221866 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 2%
Number of subjects: 746
Study 32221866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 746
Study 32222808 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin (pola) 1.0-1.8 mg/kg administered intravenously every 3 weeks (q3w) with R/G-CHP
Number of subjects: 0
Study 32222841 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32223334 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Number of subjects: 0
Study 32223740 — intervention group
Group type: EXPERIMENTAL
Intervention: mNavigator digital health application for protocol compliance in pediatric cancer treatment
Number of subjects: 0
Study 32223937 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotrectinib (oral TRK inhibitor)
Number of subjects: 1
Study 32223960 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (6-month MACEs)
Number of subjects: 8958
Study 32223960 — intervention group
Group type: COMPARATOR
Intervention: Men (6-month MACEs)
Number of subjects: 8958
Study 32223960 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (total mortality)
Number of subjects: 8958
Study 32223960 — intervention group
Group type: COMPARATOR
Intervention: Men (total mortality)
Number of subjects: 8958
Study 32223960 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular risk profile
Number of subjects: 8958
Study 32223960 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 8958
Study 32223960 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level of education and socioeconomic status
Number of subjects: 8958
Study 32223960 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall factors
Number of subjects: 8958
Study 32224030 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (GPIs)
Number of subjects: 1329
Study 32224030 — intervention group
Group type: COMPARATOR
Intervention: Non-Glycoprotein IIb/IIIa inhibitors (non-GPI)
Number of subjects: 1329
Study 32224306 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin (3.2 mg/m²)
Number of subjects: 105
Study 32224416 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab (10 mg/kg Q2W)
Number of subjects: 33
Study 32224490 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-strength rice suji with green banana
Number of subjects: 145
Study 32224490 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-strength rice suji alone
Number of subjects: 145
Study 32224490 — intervention group
Group type: COMPARATOR
Intervention: Three-quarter-strength rice suji
Number of subjects: 145
Study 32225136 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-Fit training program (standardized, ambulatory, hospital-based circuit training) performed two hours, twice weekly, for two months.
Number of subjects: 55
Study 32226189 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate enriched bread
Number of subjects: 0
Study 32226189 — intervention group
Group type: COMPARATOR
Intervention: Control bread
Number of subjects: 0
Study 32226634 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centred lifestyle and behavioural intervention, details on dosage and duration not specified.
Number of subjects: 0
Study 32226774 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined long-term androgen deprivation and pelvic radiotherapy
Number of subjects: 0
Study 32226774 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32227570 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized prophylaxis (IP) regimen
Number of subjects: 211
Study 32227570 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly prophylaxis, modified prophylaxis, or episodic treatment
Number of subjects: 211
Study 32228157 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal enhanced brain function index
Number of subjects: 0
Study 32228297 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression group (AAA with >10-mL increase in volume)
Number of subjects: 126
Study 32228297 — intervention group
Group type: COMPARATOR
Intervention: Stable group (AAA with ≤10-mL increase in volume)
Number of subjects: 126
Study 32228542 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 exposed uninfected (HEU) children
Number of subjects: 345
Study 32228542 — intervention group
Group type: COMPARATOR
Intervention: HIV-unexposed uninfected (HUU) children
Number of subjects: 345
Study 32228542 — intervention group
Group type: EXPERIMENTAL
Intervention: HEU children with caregivers' DMFT>0
Number of subjects: 345
Study 32228542 — intervention group
Group type: EXPERIMENTAL
Intervention: HEU children with dmft>0
Number of subjects: 345
Study 32228611 — intervention group
Group type: EXPERIMENTAL
Intervention: Total joint replacement of the TMC joint
Number of subjects: 287
Study 32228664 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin-impregnated biologic graft
Number of subjects: 24
Study 32229096 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 557
Study 32231244 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide association study (GWAS) for primary MN
Number of subjects: 3782
Study 32231600 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy-based validation of the Sleep Disorder Inventory
Number of subjects: 0
Study 32231600 — intervention group
Group type: COMPARATOR
Intervention: Sleep Disorder Inventory
Number of subjects: 0
Study 32231633 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional bone conduction hearing implant system
Number of subjects: 0
Study 32231633 — intervention group
Group type: COMPARATOR
Intervention: Less invasive treatment with new abutment technology
Number of subjects: 0
Study 32232048 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient positioning during surgery
Number of subjects: 0
Study 32232048 — intervention group
Group type: COMPARATOR
Intervention: Control group positioning during surgery
Number of subjects: 0
Study 32232087 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelet decomposition method applied to raw voltage data to generate mean wavelet power (MWP) features.
Number of subjects: 0
Study 32232087 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean wavelet power (MWP) features used as input to support vector machine based decoding algorithms.
Number of subjects: 0
Study 32232095 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile treatment at the cymba concha
Number of subjects: 34
Study 32232095 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile treatment in RA patients
Number of subjects: 34
Study 32232095 — intervention group
Group type: COMPARATOR
Intervention: Vibrotactile treatment at the gastrocnemius
Number of subjects: 34
Study 32232101 — intervention group
Group type: EXPERIMENTAL
Intervention: tsDCS+pDCS
Number of subjects: 26
Study 32232101 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 26
Study 32232107 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcurrent treatment administered at home for 5 mins daily for 4 weeks.
Number of subjects: 30
Study 32232108 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop neuromuscular electrical stimulation using textile-based electrodes
Number of subjects: 5
Study 32232108 — intervention group
Group type: EXPERIMENTAL
Intervention: Textile-based electrodes
Number of subjects: 5
Study 32232108 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop control methods
Number of subjects: 5
Study 32232175 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (200-285 mmHg cuff pressure)
Number of subjects: 0
Study 32232175 — intervention group
Group type: COMPARATOR
Intervention: Sham-remote ischaemic conditioning (20 mmHg cuff pressure)
Number of subjects: 0
Study 32232325 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline CDKN1B variants (pathogenic/likely pathogenic) identified in 3 patients and variants of uncertain significance in 2 patients, accounting for 2.6% of the patients screened.
Number of subjects: 211
Study 32232325 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline CDKN1B variants
Number of subjects: 211
Study 32232327 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 29
Study 32232380 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat overfeeding (65% total energy from fat, 50% above estimated energy requirements) for 7 days
Number of subjects: 15
Study 32232380 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat overfeeding
Number of subjects: 15
Study 32232399 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin stimulation test
Number of subjects: 16
Study 32232597 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-containing supplement (200 mg caffeine, 1600 mg β-alanine, 1000 mg quercetin) taken 35 minutes before exercise
Number of subjects: 13
Study 32232597 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 13
Study 32232640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemia
Number of subjects: 356
Study 32232640 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrotic range proteinuria
Number of subjects: 356
Study 32232640 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D deficiency
Number of subjects: 356
Study 32232640 — intervention group
Group type: EXPERIMENTAL
Intervention: Glomerulonephropathy as the origin of CKD
Number of subjects: 356
Study 32232640 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight or obese body mass index z-score
Number of subjects: 356
Study 32232640 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated proteinuria
Number of subjects: 356
Study 32232640 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocalcemia
Number of subjects: 356
Study 32232640 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D deficiency
Number of subjects: 356
Study 32232640 — intervention group
Group type: EXPERIMENTAL
Intervention: Glomerular filtration rate stage 3b or higher
Number of subjects: 356
Study 32232640 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperphosphatemia
Number of subjects: 356
Study 32232740 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) in combination with methotrexate (MTX)
Number of subjects: 444
Study 32232817 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab administration during RSV season
Number of subjects: 25003
Study 32232853 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe sepsis or septic shock
Number of subjects: 250827
Study 32232853 — intervention group
Group type: COMPARATOR
Intervention: Nonsepsis ICU patients
Number of subjects: 250827
Study 32233700 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 75
Study 32233700 — intervention group
Group type: COMPARATOR
Intervention: Control group (65 pregnant women without complications)
Number of subjects: 75
Study 32233741 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antihypertensive treatment
Number of subjects: 303
Study 32233741 — intervention group
Group type: COMPARATOR
Intervention: No antihypertensive treatment
Number of subjects: 303
Study 32233746 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPECTS 8-10
Number of subjects: 142
Study 32233746 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPECTS 5-7
Number of subjects: 142
Study 32233746 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ASPECTS (8-10)
Number of subjects: 142
Study 32233746 — intervention group
Group type: COMPARATOR
Intervention: ASPECTS and core infarction volume
Number of subjects: 142
Study 32233756 — intervention group
Group type: EXPERIMENTAL
Intervention: Total nut consumption increase (≥0.5 servings/day)
Number of subjects: 192655
Study 32233756 — intervention group
Group type: EXPERIMENTAL
Intervention: Total nut consumption increase (0.5 servings/day)
Number of subjects: 192655
Study 32233756 — intervention group
Group type: COMPARATOR
Intervention: Decrease in nut consumption (≥0.50 servings/day)
Number of subjects: 192655
Study 32233956 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate
Number of subjects: 0
Study 32234045 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress cardiovascular magnetic resonance (CMR) screening for silent myocardial ischaemia
Number of subjects: 63
Study 32234045 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 63
Study 32234046 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PDDI
Number of subjects: 524
Study 32234046 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate PDDI
Number of subjects: 524
Study 32234046 — intervention group
Group type: COMPARATOR
Intervention: Patients in Germany
Number of subjects: 524
Study 32234077 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxemia on day 1
Number of subjects: 2005
Study 32234077 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive oxygen use
Number of subjects: 2005
Study 32234077 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxemia and excessive oxygen use
Number of subjects: 2005
Study 32234414 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraposture-focus strategy
Number of subjects: 30
Study 32234414 — intervention group
Group type: COMPARATOR
Intervention: Posture-focus strategy
Number of subjects: 30
Study 32234475 — intervention group
Group type: EXPERIMENTAL
Intervention: Dectin-1 on myeloid cells
Number of subjects: 0
Study 32234475 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannose receptor (MR) deficiency
Number of subjects: 0
Study 32234475 — intervention group
Group type: EXPERIMENTAL
Intervention: Dectin-1 expression in DSS-exposed MR-deficient mice
Number of subjects: 0
Study 32234705 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rituximab
Number of subjects: 25
Study 32234705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 32234708 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based mindfulness program
Number of subjects: 34
Study 32234747 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga of Stress Resilience programme (group-based therapeutic yoga combining yoga and psychotherapeutic techniques)
Number of subjects: 0
Study 32234848 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC)-based immunotherapy
Number of subjects: 9
Study 32234967 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 6148
Study 32235248 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 214
Study 32236104 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counseling
Number of subjects: 264
Study 32236104 — intervention group
Group type: EXPERIMENTAL
Intervention: Social engagement
Number of subjects: 264
Study 32236104 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination
Number of subjects: 264
Study 32236104 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 264
Study 32236406 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole (ISAV) as primary antifungal prophylaxis (PAP)
Number of subjects: 65
Study 32236416 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 expression on CD4+/CD8+ T cells in mid-PR phase
Number of subjects: 98
Study 32236416 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 expression on CD8+ T cells in mid-PR
Number of subjects: 98
Study 32236416 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating Tregs and IL-35+ Tregs
Number of subjects: 98
Study 32236416 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 expression on T cells
Number of subjects: 98
Study 32236416 — intervention group
Group type: COMPARATOR
Intervention: Nonremitters
Number of subjects: 98
Study 32236441 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine infusion
Number of subjects: 146
Study 32236525 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of urinary-derived human chorionic gonadotropin (uhCG) in addition to standard immunosuppression
Number of subjects: 26
Study 32236717 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure (LAAC) procedure
Number of subjects: 619
Study 32236732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 0
Study 32236732 — intervention group
Group type: COMPARATOR
Intervention: Non-ertugliflozin (glimepiride or placebo)
Number of subjects: 0
Study 32236819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca/P ratio above 2.55 for PHPT patients
Number of subjects: 1038
Study 32236819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca/P ratio below 1.78 for HypoPT patients
Number of subjects: 1038
Study 32236819 — intervention group
Group type: COMPARATOR
Intervention: Ca/P ratio in PHPT patients
Number of subjects: 1038
Study 32236819 — intervention group
Group type: COMPARATOR
Intervention: Ca/P ratio in HypoPT patients
Number of subjects: 1038
Study 32236861 — intervention group
Group type: EXPERIMENTAL
Intervention: Missense variant rs17117699 in OMA1 in group without β-blocker use
Number of subjects: 3324
Study 32236861 — intervention group
Group type: COMPARATOR
Intervention: Missense variant rs17117699 in OMA1 in group with β-blocker use
Number of subjects: 3324
Study 32236861 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional analysis of rs17117699-G allele
Number of subjects: 3324
Study 32236861 — intervention group
Group type: COMPARATOR
Intervention: Functional analysis of rs17117699-T allele
Number of subjects: 3324
Study 32237015 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Cardiorespiratory Fitness (CRF)
Number of subjects: 115
Study 32238160 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased hospital volume
Number of subjects: 759928
Study 32238160 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased hospital volume
Number of subjects: 759928
Study 32238160 — intervention group
Group type: COMPARATOR
Intervention: Unchanged hospital volume
Number of subjects: 759928
Study 32238340 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Respiratory Infection Diagnostic Aid (ARIDA)
Number of subjects: 290
Study 32238340 — intervention group
Group type: EXPERIMENTAL
Intervention: Two ARIDA devices
Number of subjects: 290
Study 32238341 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time feedback via the point-of-care (POC) urine test
Number of subjects: 100
Study 32238341 — intervention group
Group type: COMPARATOR
Intervention: Standard of care adherence counseling
Number of subjects: 100
Study 32238343 — intervention group
Group type: EXPERIMENTAL
Intervention: mDASHNa-CC app
Number of subjects: 60
Study 32238515 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus maintenance therapy
Number of subjects: 1355
Study 32238921 — intervention group
Group type: EXPERIMENTAL
Intervention: MRX34 with oral dexamethasone premedication, given intravenously daily for 5 days in 3-week cycles.
Number of subjects: 85